Time–outcome relationship in acute large-vessel occlusion exists across all ages: subanalysis of RESCUE-Japan Registry 2

Kenichi Todo1,2, Shinichi Yoshimura2, Kazutaka Uchida2, Hiroshi Yamagami3,4, Nobuyuki Sakai2, Haruhiko Kishima2, Hideki Mochizuki2, Masayuki Ezura2, Yasushi Okada2, Kazuo Kitagawa3, Kazumi Kimura3, Makoto Sasaki4, Norio Tanahashi4, Kazunori Toyoda6, Eisuke Furu1,2, Yuji Matsumaru1, Kazuo Minematsu4, Takaya Kitano1, Shuhei Okazaki2, Tsutomu Sasaki2, Manabu Sakaguchi2, Masatoshi Takagaki2, Takeo Nishida7, Kazuo Minematsu2, Takeshi Morimoto14 & RESCUE-Japan Registry 2 Investigators*

Early reperfusion after endovascular thrombectomy is associated with an improved outcome in ischemic stroke patients; however, the time dependency in elderly patients remains unclear. We investigated the time–outcome relationships in different age subgroups. Of 2420 patients enrolled in the RESCUE-Japan Registry 2 study, a study based on a prospective registry of stroke patients with acute cerebral large-vessel occlusion at 46 centers, we analyzed the data of 1010 patients with successful reperfusion after endovascular therapy (mTICI of 2b or 3). In 3 age subgroups (< 70, 70 to < 80, and ≥ 80 years), the mRS scores at 90 days were analyzed according to 4 categories of onset-to-reperfusion time (< 180, 180 to < 240, 240 to < 300, and ≥ 300 min). In each age subgroup, the distributions of mRS scores were better with shorter onset-to-reperfusion times. The adjusted common odds ratios for better outcomes per 1-category delay in onset-to-reperfusion time were 0.66 (95% CI 0.55–0.80) in ages < 70 years, 0.66 (95% CI 0.56–0.79) in ages 70 to < 80 years, and 0.83 (95% CI 0.70–0.98) in ages ≥ 80 years. Early reperfusion was associated with better outcomes across all age subgroups. Achieving early successful reperfusion is important even in elderly patients.

Randomized clinical trials have demonstrated that endovascular thrombectomy for acute large-vessel occlusion has beneficial effects on 90-day outcomes1–4. Furthermore, a shorter time to successful reperfusion after endovascular thrombectomy has been demonstrated to be associated with better functional outcomes7–10. Although older age is a strong predictor of worse outcomes in stroke patients11, the treatment effect of endovascular thrombectomy has been proven to be consistent across all ages1; thus, guidelines recommend endovascular therapy even in octogenarians12. However, the effect of a shorter time to reperfusion in elderly patients remains controversial13,14. Therefore, we sought to identify the time–outcome relationship in elderly patients. For this

1Stroke Center, Osaka University Hospital, Suita, Osaka, Japan. 2Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan. 3Department of Stroke Neurology, National Hospital Organization Osaka National Hospital, Osaka, Japan. 4Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan. 5Department of Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan. 6Department of Neurosurgery, National Hospital Organization Sendai Medical Center, Sendai, Miyagi, Japan. 7Cerebrovascular Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. 8Department of Neurology, Tokyo Women’s Medical University, Tokyo, Japan. 9Department of Neurological Science, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. 10Institute for Biomedical Sciences, Iwate Medical University, Morioka, Iwate, Japan. 11Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan. 12Department of Stroke Neurology, Saiseikai Toyama Hospital, Toyama, Japan. 13Division for Stroke Prevention and Treatment, Department of Neurosurgery, University of Tsukuba, Tsukuba, Ibaraki, Japan. 14Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan. * A list of authors and their affiliations appears at the end of the paper. **email: ktodo@neurol.med.osaka-u.ac.jp
purpose, we analyzed the association of onset-to-reperfusion time (ORT) with outcomes in different age subgroups using a large practice-based database.

**Methods**

**Ethics statement.** This study complied with the Declaration of Helsinki guidelines for investigations involving humans, and all methods were performed in accordance with relevant guidelines and regulations for observational studies. The study design and protocols were approved by the institutional review boards of all participating centers. Approving institutional review boards waived the need for informed consent because we used clinical information obtained in routine clinical practice. The institutional review boards of all participating centers approved the exemption in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan. The full names of all institutional review boards are as follows: Institutional review boards of Red Cross Ise Hospital, Ube Industries Central Hospital, Ogaki Tokushukai Hospital, Osaka Medical College, Osaka University Hospital, Kagawa University, Kawasaki Medical School Hospital, Kanazawa Medical University Hospital, Kitasato University, Gifu University, Kyushu Medical Center, Red Cross Kyoto Daiichi Hospital, Kinki University, Kurashiki Central Hospital, Kurume University Hospital, Kanann Hospital, Kobe City Medical Center General Hospital, Kokura Memorial Hospital, National Cerebral and Cardiovascular Center, Saiseikai Toyama Hospital, Saiseikai Nagasaki Hospital, Saitama Medical University International Medical Center, Sapporo Medical University, Shimizu Hospital, Juntendo University Hospital, Seisho Hospital, National Hospital Organization Sendai Medical Center, Koseikai Takeda Hospital, Tanushimaru Central Hospital, Tama Medical Center, Tokushima University, Toranomon Hospital, Nagoya University, Red Cross Nagoya Daini Hospital, Nippon Medical School, Hakodate Shintoshi Hospital, Hakodate Neurosurgical Hospital, Hyogo College of Medicine, Hyogo Brain and Heart Center, Hiroaki University, Hiroshima University, Red Cross Fukui Hospital, Fukuoka University Chikusho Hospital, Mazda Hospital, Mie University Hospital, Miyakonjo Medical Association Hospital, Yamaguchi Prefectural Grand Medical Center, Yamaguchi University and Yokohamashintoshi Neurosurgical Hospital.

**Subjects.** This study is a post-hoc analysis of RESCUE-Japan Registry 2\(^{15}\), which was a prospective multicenter registry that enrolled 2420 patients with acute cerebral large-vessel occlusion at 46 centers in Japan between October 1, 2014 and September 30, 2016. RESCUE-Japan Registry 2 was designed to clarify the generalizability of the effectiveness of endovascular therapy in real-world patients. We enrolled consecutive patients aged 20 years who were hospitalized within 24 h of the onset of acute cerebral large-vessel occlusion.

**Imaging and endovascular therapy.** The diagnostic and treatment modalities were not unified in the RESCUE-Japan Registry 2. The Alberta Stroke Program Early Computerized Tomography Score (ASPECTS) was derived from computed tomography (CT) or magnetic resonance diffusion-weighted imaging (DWI)\(^{16,17}\). In patients with stroke in the posterior circulation, we measured the posterior circulation ASPECTS (p-ASPECTS) using DWI\(^{18}\). The treatment modalities were determined by the attending physician. In this study, endovascular therapy included thrombectomy using stent retrievers and/or aspiration catheters, balloon angioplasty, stenting, intra-arterial fibrinolysis, piercing using guidewires and/or microcatheters, or a combination of these treatments, all of which have been approved in Japan. The stent retrievers used in this study were the Solitaire® 2 revascularization device (Covidien, Irvine, CA), the Trevo® ProVue retriever/Trevo® XP ProVue retriever (Stryker, Fremont, CA), and the Revive® retriever (Codman, Raynham, MA). The aspiration catheter used was the Penumbra® system (Penumbra, Alameda, CA). Other devices for endovascular therapy procedures such as stenting or angioplasty were selected by the physicians in charge.

**Variables and measurements.** We obtained clinical information of patients from hospital charts. Follow-up information up to 90 days was collected primarily through a review of the hospital charts or by contacting the patients, relatives, and/or physicians. We used the following clinical data for the analyses in the current study: age, sex, vascular risk factors (i.e., atrial fibrillation, hypertension, and diabetes mellitus), pre-stroke modified Rankin Scale (mRS) score\(^{19}\), National Institute of Health Stroke Scale (NIHSS) score\(^{20}\), blood glucose level on admission, systolic blood pressure on admission, location of occlusion, use of intravenous recombinant tissue plasminogen activator (IV-rtPA), ASPECTS, onset-to-puncture time (OPT), ORT, modified thrombolysis in cerebral infarction (mTICI) score (0, no perfusion; 1, minimal perfusion; 2a, reperfusion of less than half of the previously occluded territory; 2b, reperfusion of more than half of the previously occluded territory; 3, complete reperfusion)\(^{21,22}\), symptomatic intracranial hemorrhage (sICH), and mRS score at 90 days after stroke. sICH was defined as intracranial hemorrhage within 72 h after stroke with neurological worsening of ≥ 4 points in the NIHSS score\(^{22}\). OPT and ORT were defined as the duration from the time that the patient was last seen to be well to the groin puncture and the end of the endovascular therapy, respectively. We defined successful reperfusion as an mTICI score of ≥ 2b.

We divided the patients into 3 age subgroups: < 70, 70 to < 80, and ≥ 80 years. Since the time–outcome relationship was demonstrated in patients with OPT of 6 h or less\(^{5–10}\), but not in patients with OPT of more than 6 h\(^{23,24}\), we focused on the early time window and divided ORT into 4 categories with thresholds of 180, 240, and 300 min. We compared the clinical background characteristics and outcome measurements according to the ORT categories in each age subgroup.

The primary outcome was set as the ordinal score on the mRS score at 90 days after stroke. The secondary outcomes were set as a good outcome (defined as mRS score ≤ 2) and mortality at 90 days after stroke. The safety outcome was defined as the occurrence of an sICH within 72 h after stroke.
Statistical analyses. We analyzed the database of patients with successful reperfusion after endovascular therapy (mTICI score 2b or 3). We analyzed continuous variables using the Mann–Whitney U test or Kruskal–Wallis test, and expressed them as median values and interquartile ranges. We analyzed categorical data using the chi-square test, and expressed them as numbers and percentages. In each age subgroup, the trends in the distributions of mRS scores were analyzed according to the ORT categories using the Jonckheere–Terpstra test. We developed multivariate logistic regression models to assess the association between ORT and outcomes by adjusting for the following clinically relevant factors: ASPECTS (≥ 6 or < 6), NIHSS score, pre-stroke mRS score, use of IV-rtPA, site of the main occlusions (anterior or posterior circulation), and vessels of the main occlusions (internal carotid artery [ICA] and M1 segment of the middle cerebral artery occlusion or other arteries). ORT was entered as a categorical or a continuous variable. Because the threshold of 6 for both anterior circulation ASPECTS and pc-ASPECTS was reported to show good discrimination ability25,26, we dichotomized both scores according to whether they were above or below 6. If both CT and DWI were performed before endovascular therapy, we used ASPECTS on DWI in patients with anterior circulation occlusion. We used pc-ASPECTS in patients with stroke in the posterior circulation. To assess potential selection bias, we performed sensitivity analyses. First, we developed multivariate logistic regression models using the multiple imputation method (Supplementary Methods). Second, we analyzed the database of patients with an OPT of ≤ 6 h. Third, we developed multivariate logistic regression model using ASPECTS on CT in patients with both ASPECTS on DWI and CT.

Statistical significance was set at P < 0.05. We conducted all analyses with R software using the rms package (version 3.3.3; F Foundation for Statistical Computing, Vienna, Austria)27.

Results
Baseline characteristics. Among 2420 enrolled patients, 21 patients were excluded because 12 patients did not meet the eligibility criteria and 9 patients were lost to follow-up. Of the remaining 2399 patients, 1278 patients underwent endovascular therapy. Among them, 177 patients with unsuccessful reperfusion (mTICI 0–2a) and 7 patients without reperfusion time data were excluded. Patients without data of ASPECTS, NIHSS score, or mRS score before stroke were also excluded. Thus, 1010 patients were included in the analysis (Fig. 1).

Clinical characteristics according to the age subgroups are shown in Table 1. The proportions of patients with female sex, hypertension, atrial fibrillation, and pre-stroke mRS score > 2 were higher in the elderly subgroups. The NIHSS score and systolic blood pressure were higher in elderly patients. The proportion of patients with diabetes mellitus, IV-rtPA use, and ASPECTS ≥ 6 were not different among the age subgroups. The blood glucose level, location of the occlusion, OPT, and ORT were not different among the age subgroups.

The clinical characteristics according to the ORT categories in each age subgroup are shown in Supplementary Tables S1–S3. The proportion of patients with atrial fibrillation and an NIHSS score were higher in the shorter ORT categories in patients aged ≤ 80 years. The proportion of patients with IV-rtPA use was lower in those with an ORT > 300 min. The proportion of patients with ASPECTS ≥ 6 in patients aged < 70 years and the proportion of patients with ICA or M1 segment occlusion in patients aged 70 to < 80 years was different among the ORT categories.
Primary outcomes. The shorter ORT categories were associated with better distributions of mRS scores at 90 days in each age subgroup (Fig. 2). The adjusted common odds ratios for better outcomes per 1-category delay in ORT were 0.66 (95% confidence interval [CI], 0.55–0.80) in patients aged < 70 years, 0.66 (95% CI 0.56–0.79) in patients aged 70 to < 80 years, and 0.83 (95% CI 0.70–0.98) in patients aged ≥ 80 years (Table 2). These adjusted common odds ratios were significantly different among age subgroups (interaction P = 0.031).

Secondary outcomes. Of the 1010 patients with successful reperfusion, we analyzed 897 patients with pre-stroke mRS scores ≤ 2. In patients aged < 70 years and 70 to < 80 years, the proportion of good outcomes was higher in the shorter ORT categories (Fig. 3). The adjusted odds ratios for a good outcome per 1-category delay in ORT were 0.52 (95% CI 0.39–0.68) in patients aged < 70 years, 0.62 (95% CI 0.49–0.78) in patients aged 70 to < 80 years, and 0.76 (95% CI 0.60–0.96) in patients aged ≥ 80 years (Table 2). Using an ORT of < 180 min as a reference, the adjusted odds ratios for a good outcome in patients with an ORT of 180 to < 240, 240 to < 300, and ≥ 300 min were as follows: in patients aged < 70 years, 0.19 (95% CI 0.069–0.55), 0.19 (95% CI 0.058–0.59), and 0.85 (95% CI 0.031–0.24); in patients aged 70 to < 80 years, 0.37 (95% CI 0.17–0.82), 0.27 (95% CI 0.12–0.61), and 0.21 (95% CI 0.096–0.44); and in patients aged ≥ 80 years, 0.78 (95% CI 0.35–1.76), 0.42 (95% CI 0.17–1.05), and 0.46 (95% CI 0.22–0.97), respectively (Fig. 3).

Although a marginal association between delayed ORT and mortality was observed in patients aged 70 to < 80 years, no associations between ORT and mortality were found in the other age subgroups. The adjusted odds ratios for mortality per 1-category delay in ORT were 1.36 (95% CI 0.82–2.26) in patients aged < 70 years,

---

**Table 1.** Clinical characteristics according to age. ACA anterior cerebral artery, ASPECTS Alberta Stroke Program Early Computed Tomography Score, BA basilar artery, CT computed tomography, DWI diffusion-weighted imaging, ICA internal carotid artery, IV-rtPA intravenous recombinant tissue plasminogen activator, IQR interquartile range, MCA middle cerebral artery, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, PCA posterior cerebral artery, VA vertebral artery. *ASPECTS was derived from CT or DWI. If both CT and DWI were performed before endovascular therapy, ASPECTS on DWI was used for the analysis. In patients with stroke in the posterior circulation, posterior circulation ASPECTS on DWI was used for the analysis.
1.59 (95% CI 1.01–2.50) in patients aged 70 to < 80 years, and 0.88 (95% CI 0.63–1.22) in patients aged ≥ 80 years (Table 2). There was no heterogeneity with respect to the age subgroups (interaction \( P = 0.054 \)). Differences in the mortality rate among the ORT categories were found in patients aged < 70 years, but not in patients aged 70 to < 80 or ≥ 80 years (Supplementary Table S4).

Safety outcomes. The adjusted odds ratios for sICH per 1-category delay in ORT were 0.98 (95% CI 0.57–1.69) in patients aged < 70 years, 1.21 (95% CI 0.72–2.03) in patients aged 70 to < 80 years, and 0.90 (95% CI 0.58–1.41) in patients aged ≥ 80 years. (Table 2). There was no heterogeneity with respect to age subgroups (interaction \( P = 0.75 \)). No difference in the rate of sICH among the ORT categories was observed in any age subgroup (Supplementary Table S4).

Sensitivity analysis. After the imputation of missing data using the multiple imputation method, the adjusted common odds ratios for better outcomes per 1-category delay in ORT were 0.66 (95% CI 0.55–0.79) in patients aged < 70 years, 0.67 (95% CI 0.56–0.79) in patients aged 70 to < 80 years, and 0.79 (95% CI 0.67–0.93) in patients aged ≥ 80 years (Supplementary Table S5), which also showed a significant time–outcome relationship in all age subgroups. These adjusted common odds ratios were not different among the age subgroups (interaction \( P = 0.087 \)). Of the 1010 patients, we analyzed 700 patients with an OPT of ≤ 6 h. Obvious time–outcome relationships were observed across all age subgroups. The adjusted common odds ratios for better outcomes per 1-category delay in ORT were 0.66 (95% CI 0.55–0.79) in patients aged < 70 years, 0.67 (95% CI 0.56–0.79) in patients aged 70 to < 80 years, and 0.79 (95% CI 0.67–0.93) in patients aged ≥ 80 years (Supplementary Table S5). These adjusted common odds ratios were not different among the age subgroups (interaction \( P = 0.24 \)). The adjusted common odds ratios for better outcomes per 30-min delay in ORT were 0.89 (95% CI 0.62–0.87) in patients aged < 70 years, 0.88 (95% CI 0.79–0.92) in patients aged 70 to < 80 years, and 0.89 (95% CI 0.82–0.96) in patients aged ≥ 80 years (Supplementary Table S5). These adjusted common odds ratios were not different among the age subgroups (interaction \( P = 0.90 \)). In patients who underwent both CT and DWI before endovascular therapy in patients with anterior circulation occlusion, we used ASPECTS on CT for sensitivity analysis instead of ASPECTS on DWI. The adjusted common odds ratios for better outcomes per 1-category delay in ORT were 0.64 (95% CI 0.54–0.78) in patients...
Table 2. Adjusted odds ratios for outcomes according to ORT. CI confidence interval, mRS modified Rankin Scale, mTICI modified thrombolysis in cerebral infarction, ORT onset-to-reperfusion time, sICH symptomatic intracranial hemorrhage. *Adjustment was made for the Alberta Stroke Program Early Computed Tomography Score (ASPECTS) (≥ 6 or < 6), National Institutes of Health Stroke Scale score, use of intravenous recombinant tissue plasminogen activator, site of the main occlusions (anterior or posterior circulation), and vessels of the main occlusions (internal carotid artery and M1 segment of the middle cerebral artery occlusion or other arteries). ASPECTS was derived from computed tomography (CT) or magnetic resonance diffusion-weighted imaging (DWI). If both CT and DWI were performed before endovascular therapy, ASPECTS on DWI was used for the analysis. In patients with stroke in the posterior circulation, posterior circulation ASPECTS on DWI was used for the analysis. ‡ORT was divided into four categories: < 180, 180 to < 240, 240 to < 300, and ≥ 300 min.

| Outcome                  | Subjects                          | Effect variable | Age subgroups | Adjusted values* (95% CI) | P for interaction |
|--------------------------|-----------------------------------|-----------------|---------------|---------------------------|------------------|
| **Primary outcome**      |                                   |                 |               |                           |                  |
| mRS score at 90 days     | 1010 patients with mTICI scores ≥ 2b | Common odds ratios per 1-category delay in ORT" | < 70 years (N = 303) | 0.66 (0.55–0.80)          |                  |
|                          |                                   |                 | 70 to < 80 years (N = 337) | 0.66 (0.56–0.79)          | 0.031            |
|                          |                                   |                 | ≥ 80 years (N = 370)    | 0.83 (0.70–0.98)          |                  |
| **Secondary outcomes**   |                                   |                 |               |                           |                  |
| mRS score ≤ 2 at 90 days | 897 patients with mTICI scores ≥ 2b and pre-stroke mRS score ≤ 2 | Odds ratios per 1-category delay in ORT" | < 70 years (N = 291)    | 0.52 (0.39–0.68)       |                  |
|                          |                                   |                 | 70 to < 80 years (N = 310) | 0.62 (0.49–0.78)          | 0.016            |
|                          |                                   |                 | ≥ 80 years (N = 296)    | 0.76 (0.60–0.96)          |                  |
| Mortality at 90 days     | 1010 patients with mTICI scores ≥ 2b | Odds ratios per 1-category delay in ORT" | < 70 years (N = 303)    | 1.36 (0.82–2.26)         |                  |
|                          |                                   |                 | 70 to < 80 years (N = 337) | 1.59 (1.01–2.50)          | 0.054            |
|                          |                                   |                 | ≥ 80 years (N = 370)    | 0.88 (0.63–1.22)          |                  |
| **Safety outcome**       |                                   |                 |               |                           |                  |
| sICH within 72 h         | 1010 patients with mTICI scores ≥ 2b | Odds ratios per 1-category delay in ORT" | < 70 years (N = 303)    | 0.98 (0.57–1.69)         |                  |
|                          |                                   |                 | 70 to < 80 years (N = 337) | 1.21 (0.72–2.03)          | 0.75             |
|                          |                                   |                 | ≥ 80 years (N = 370)    | 0.90 (0.58–1.41)          |                  |

Discussion
In this current post-hoc analysis of a large clinical registry of patients with acute cerebral large-vessel occlusion, earlier reperfusion was associated with better outcomes across all age subgroups. To the best of our knowledge, this is the first report to show the time–outcome relationship in elderly patients using a large clinical registry. Our findings confirmed that achieving early successful reperfusion is important in patients of all ages.

Previous studies have investigated the association between ORT and outcomes in different age subgroups; however, the results in the elderly subgroup differed between studies13,14. One of two studies showed that ORT was independently associated with a favorable outcome at 90 days in 34 patients aged ≥ 80 years13, whereas the other study did not find an association between ORT and a good functional outcome in 78 patients aged > 80 years with mTICI of 2b or 314. In elderly patients, because of the severe stroke outcome11, it is difficult to show a small difference according to ORT. Given the retrospective nature of the study, an age-related selection bias for endovascular therapy may have influenced the difficulty in demonstrating the differences. The present study is important in that it showed the time–outcome relationship in patients of all ages, although the relationship was small and partial in elderly patients. Logistic regression models for primary outcome (mRS at 90 days) and good outcome (mRS ≤ 2 at 90 days) showed heterogeneity among age subgroups; however, the time–outcome relationship existed across all age subgroups (Table 2). In patients aged ≥ 80 years, the proportion of good outcomes according to ORT categories was not significantly different, but was significantly smaller in patients with ORT ≥ 300 min after adjustment for confounders (Fig. 3). In patients with OPT of 6 h or less, shorter time to reperfusion was consistently associated with better outcomes across all age subgroups without heterogeneity (Supplementary Table S5). Thus, a shorter time to reperfusion is important for all ages.

We assessed the effects of early reperfusion in consecutive patients who were hospitalized within 24 h of the onset of acute large-vessel occlusion. However, randomized clinical trials using imaging-based selection criteria showed that there was no time–outcome relationship in patients with late hospital arrival23,24. Furthermore, a large database showed that the time–outcome relationships were stronger in patients with an OPT of ≤ 270 min than in those with an OPT of > 270 min10. Based on these previous reports, we set ORT categories with thresholds of 180, 240, and 300 min, and performed a sensitivity analysis in patients with an OPT of ≤ 6 h. Consequently, we focused on the early time window and observed consistent time–outcome relationships across all ages. However, we did not intend to determine the time limit for endovascular therapy. Our registry previously revealed that endovascular reperfusion therapy is effective, regardless of the onset-to-door time15.

Although a marginal association of early reperfusion with survival was observed in patients aged 70 to < 80 years, no associations were noted between ORT and mortality in the other age subgroups. In addition,
no association between ORT and sICH was found in any age subgroup. Previous reports from the meta-analysis of the HERMES collaborators and a large practical database documented that both mortality and sICH were not associated with the onset-to-randomization time or OPT\(^1\),\(^2\), which is consistent with our current results. However, in patients aged \(\geq 80\) years, the odds ratios for mortality and sICH tended to be low. This may also be due to an age-related selection bias for endovascular therapy.

The clinical background characteristics in the present study were not different from those in previous reports. Male sex\(^1\),\(^3\), hypertension\(^1\), cardiogenic embolism\(^1\), and high NIHSS score\(^1\) have been reported to be associated with elderly patients undergoing endovascular thrombectomy. Early hospital arrival was reported to be associated with atrial fibrillation, a high NIHSS score, and ambulance use in ischemic stroke patients\(^2\). This may be because atrial fibrillation is associated with stroke severity\(^3\). In our cohort, the proportion of patients with ASPECTS \(\geq 6\) in patients aged \(< 70\) years and the proportion of those with ICA or M1 segment occlusion in patients aged of \(70\) to \(< 80\) years was different among the ORT categories, although there were no trends according to ORT.

Several limitations of the current study should be noted. First, this was an observational study; thus, the selection of endovascular therapy depended on the practicing physician. Moreover, patients with unsuccessful reperfusion were excluded from the analysis. Furthermore, 8% of patients were excluded from the analysis owing to missing data. These factors may have led to a potential selection bias, although we conducted sensitivity analyses. Second, although we systematically registered stroke patients with acute large-vessel occlusion over a 2-year period at 46 centers, the sample size was not large enough to fully evaluate the time–outcome effect in each age subgroup. Third, the imaging methods were not standardized and perfusion imaging was not analyzed in this study. We used two types of ASPECTS: ASPECTS on CT, an ASPECTS on DWI in patients with anterior circulation occlusion. Although we conducted a sensitivity analysis, this was not sufficient to adjust for the impact of imaging on the outcome. Fourth, the assessments of the mRS scores could be biased, as acute treatment was not completely masked although the assessments were performed by independent physicians. Fifth, the assessments of the mTICI scores could be biased. A previous report revealed a discrepancy in the assessment of the mTICI score between local operators and independent core laboratories\(^4\). This may have led to a selection bias.

**Conclusions**

Our large prospective registry of acute large-vessel occlusion revealed that early reperfusion was associated with better outcomes across all age subgroups. Achieving early successful reperfusion is important in patients of all ages, even in octogenarians.
Data availability

The data, analytic methods, and study materials will not be made available to other researchers for the purpose of reproducing the results or replicating the procedure.

Received: 21 September 2020; Accepted: 4 June 2021
Published online: 17 June 2021

References

1. Goyal, M. et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387, 1723–1731 (2016).
2. Bracard, S. et al. Mechanical thrombectomy intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol. 15, 1138–1147 (2016).
3. Mocco, J. et al. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone. Stroke 47, 2331–2338 (2016).
4. Muir, K. W. et al. Endovascular therapy for acute ischaemic stroke: the pragmatic ischaemic stroke thrombectomy evaluation (PISTE) randomised, controlled trial. J. Neurol. Neurosurg. Psychiatry 88, 38–44 (2017).
5. Nogueira, R. G. et al. Thrombectomy 6 to 24 h after stroke with a mismatch between deficit and infarct. N. Engl. J. Med. 378, 11–21 (2018).
6. Albers, G. W. et al. Thrombectomy for stroke at 6 to 16 h with selection by perfusion imaging. N. Engl. J. Med. 378, 708–718 (2018).
7. Mueller-Kronast, N. H. et al. Systematic evaluation of patients treated with neurothrombectomy devices for acute ischemic stroke: primary results of the STRATIS registry. Stroke 48, 2760–2767 (2017).
8. Saver, J. L. et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA 316, 1279–1288 (2016).
9. Sheth, S. A. et al. Time to endovascular reperfusion and degree of disability in acute stroke. Ann. Neurol. 78, 584–593 (2015).
10. Jahan, R. et al. Association between time to treatment with endovascular reperfusion therapy and outcomes in patients with acute ischemic stroke treated in clinical practice. JAMA 322, 252–263 (2019).
11. Fonarow, G. C. et al. Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke. Circulation 121, 879–891 (2010).
12. Powers, W. J. et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 46, 3020–3035 (2015).
13. Son, S., Kang, D. H., Hwang, Y. H., Kim, Y. S. & Kim, Y. W. Efficacy, safety, and clinical outcome of modern mechanical thrombectomy in elderly patients with acute ischemic stroke. Acta Neurochir. (Wien) 159, 1663–1669 (2017).
14. Koizumi, S. et al. Onset to reperfusion time was not important in mechanical thrombectomy for elderly patients: a retrospective multicenter study in Tama area. Cerebrovasc. Dis. 46, 89–96 (2018).
15. Yoshimura, S. et al. Endovascular therapy in ischemic stroke with acute large-vessel occlusion: recovery by endovascular salvage for cerebral ultra-acute embolism Japan registry 2. J. Am. Heart Assoc. 7, e008796. https://doi.org/10.1161/JAHA.118.008796 (2018).
16. Barber, P. A., Demchuk, A. M., Zhang, J. & Buchan, A. M. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 355, 1670–1674 (2000).
17. Barber, P. A. et al. Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry 76, 1528–1533 (2005).
18. Tei, H., Uchiyama, S., Usui, T. & Ohara, K. Posterior circulation ASPECTS on diffusion-weighted MRI can be a powerful marker for predicting functional outcome. J. Neurol. 257, 767–773 (2010).
19. van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J. & van Gijn, J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19, 604–607 (1988).
20. Lyden, P. et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 25, 2220–2226 (1994).
21. Zaidat, O. O. et al. Recommendations on angiographic recanalization grading standards for acute ischemic stroke: a consensus statement. Stroke 44, 2650–2663 (2013).
22. Walthgren, N. et al. Thrombolyis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369, 275–282 (2007).
23. Lansberg, M. G. et al. Association of thrombectomy with stroke outcomes among patient subgroups: secondary analyses of the DEFUSE 3 randomized clinical trial. JAMA Neurol. 76, 447–453 (2019).
24. Tekle, W. G. et al. Impact of periprocedural and technical factors and patient characteristics on revascularization and outcome in the DAWN trial. Stroke 51, 247–253 (2020).
25. Kaesmacher, J. et al. Mechanical thrombectomy in ischemic stroke patients with alberta stroke program early computed tomography score 0–5. Stroke 50, 880–888 (2019).
26. Luo, G. et al. Factors associated with 90-day outcomes of patients with acute posterior circulation stroke treated by mechanical thrombectomy. World Neurosurg. 109, e318–e328 (2018).
27. Package ‘rms’. https://cran.r-project.org/web/packages/rms/rms.pdf. Accessed 27 May 2016.
28. Matsuo, R. et al. Association between onset-to-door time and clinical outcomes after ischemic stroke. Stroke 48, 3049–3056 (2017).
29. Kimura, K., Minematsu, K., Yamaguchi, T. & Japan Multicenter Stroke Investigators’ Collaboration (I-MUSIC). Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischemic stroke. J. Neurol. Neurosurg. Psychiatry 76, 679–683 (2005).
30. Zhang, G. et al. Operator versus core lab adjudication of reperfusion after endovascular treatment of acute ischemic stroke. Stroke 49, 2376–2382 (2018).

Acknowledgements

We thank all investigators involved in RESCUE (Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism)-Japan Registry 2. This study was supported in part by the Japan Agency for Medical Research and Development; the Japanese Society for Neuroendovascular Therapy; the Ministry of Health, Labor and Welfare of Japan; Medtronic; Stryker; and Medicos Hirata. The funding sources did not participate in any part of the study, from study conception to article preparation.
**Author contributions**
Ke.T., S.Y., K.U. and M.T. designed and conceptualized the study. Ke.T. analyzed the data and drafted the manuscript for intellectual content. S.Y., K.U., H.Y., N.S. and T.M. had major roles in the acquisition of data. Ke.T., S.Y., K.U., H.Y., N.S., H.K., H.M., M.E., Y.O., KazuK, KazumiK, Mak.S., N.T., Ka.T., E.F., Y.M., K.M., T.K., S.O., T.S., Man.S, M.T., T.N., H.N., and T.M. revised the manuscript for intellectual content.

**Competing interests**
Dr. Todo reports lecturer fees from Medtronic and Stryker. Dr. Yoshimura reports research grants from Medico’s Hirata, Medtronic, and Termo and lecturer fees from Medtronic, Keio, and Stryker. Dr. Yamagami reports research grants from Kaken, Medtronic, and Stryker; and membership in the advisory boards of Daiichi-Sankyo and Biomedical Solutions. Dr. Sakai reports a research grant from Takeda, lecturer fees from Juro, Johnson & Johnson, Medico’s Hirata, Medtronic, and Stryker; and membership in the advisory boards of Juro and Medtronic. Dr. Nakamura reports lecturer fees from Johnson & Johnson, Medtronic, and Stryker. Dr. Kimura reports lecturer fees from Medtronic. Dr. Matsumaru discloses consultant fees from Johnson & Johnson, Medico’s Hirata, Medtronic, and Stryker; and membership in the advisory boards of Medico’s Hirata and Juro. Dr. Minematsu reports lecturer fees from Medtronic and Stryker and membership in the advisory board of Medico’s Hirata. The other authors report no conflicts related to the subject matter of the article.

**Additional information**
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-92100-7.

**Correspondence** and requests for materials should be addressed to K.T.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021, corrected publication 2021

**RESCUE-Japan Registry 2 Investigators**
Kazunori Toyoda15, Masataka Takeuchi16, Masafumi Morimoto17, Toshiyuki Onda18, Masunari Shibata19, Shinichiro Yoshimura20, Nobuyuki Sakai21, Takahiro Ohta22, Keisuke Imai23, Ryo Itabashi24, Masayuki Ezura25, Taro Yamashita26, Norihito Fukawa27, Naoto Kimura28, Ryosuke Doijiri29, Hajime Ohta30, Yukiko Enomoto31, Chisaku Kanbayashi32, Ikuya Yamamura33, Hideyuki Ishihara34, Yuki Kamiya35, Makoto Hayase36, Kouhei Nishi37, Junya Kobayashi38, Hiroaki Yasuda39, Ryushi Kondo40, Daisuke Yamamoto41, Manabu Sakaguchi41, Junichiro Satomi42, Yoshihi Yagita43, Akira Handa44, Atsushi Shindo45, Nagayasu Hiyama46, Naoki Toma47, Tomoyuki Tsumoto48, Kazumi Kimura49, Wataru Tsuruta50, Keigo Matsumoto51, Yoshihiro Kiura52, Takaaki Yamazaki53, Taketo Hatano54, Yoshihisa Matsumoto55, Takao Kojima56, Norio Ikeda57, Shigeyuki Sakamoto58, Hiroyuki Ohnishi59, Koichi Haraguchi60 & Naoyuki Uchiyama61

15Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan. 16Department of Neurosurgery, Seiho Hospital, Odawara, Kanagawa, Japan. 17Department of Neurosurgery, Yokohama Shintosho Neurosurgical Hospital, Yokohama, Kanagawa, Japan. 18Department of Neurosurgery, Sapporo Shiroishi Memorial Hospital, Sapporo, Hokkaido, Japan. 19Department of Neuroendovascular Treatment, Japanese Red Cross Ise Hospital, Ise, Mie, Japan. 20Department of Neurosurgery, Nishinomiya, Hyogo, Japan. 21Department of Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan. 22Department of Neurosurgery, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo, Japan. 23Department of Neuroendovascular Treatment, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan. 24Department of Stroke Neurology, Kohoku Hospital, Senda, Miyagi, Japan. 25Department of Neurosurgery, National Hospital Organization Sendai Medical Center, Sendai, Miyagi, Japan. 26Department of Neurosurgery, Shimizu Hospital, Kyoto, Japan. 27Department of Neurosurgery, Kinki University, Osaka-Sayama, Osaka, Japan.
20Department of Neurosurgery, Iwate Prefectural Central Hospital, Morioka, Iwate, Japan. 21Department of Neurology, Iwate Prefectural Central Hospital, Morioka, Iwate, Japan. 22Department of Neurosurgery, Miyakonojo Medical Association Hospital, Miyakonojo, Miyazaki, Japan. 23Department of Neurosurgery, Gifu University Hospital, Gifu, Japan. 24Department of Neurosurgery, Kawasaki Sawai Hospital, Kawasaki, Kanagawa, Japan. 25Department of Neurosurgery, Yoshida Hospital and Cerebrovascular Research Institute, Kobe, Hyogo, Japan. 26Department of Neurosurgery, Yamaguchi University Hospital, Ube, Japan. 27Department of Neurology, Showa University Koto-Toyosu Hospital, Tokyo, Japan. 28Department of Neurosurgery, Fukui Red Cross Hospital, Fukui, Japan. 29Department of Neurosurgery, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan. 30Department of Vascular Neurology, Osaka-Minami Medical Center, Kawachinagano, Osaka, Japan. 31Department of Neurosurgery, Yamaguchi Prefectural Grand Medical Center, Yamaguchi, Japan. 32Department of Neurosurgery, Kitasato University Hospital, Sagamihara, Kanagawa, Japan. 33Department of Neurology, Osaka University Hospital, Suita, Osaka, Japan. 34Department of Neurosurgery, Tokushima University Hospital, Tokushima, Japan. 35Department of Stroke Medicine, Kawasaki Medical School Hospital, Kurashiki, Okayama, Japan. 36Department of Neurosurgery, Kurashiki Central Hospital, Kurashiki, Okayama, Japan. 37Department of Neurological Surgery, Kagawa University Faculty of Medicine, Miki, Kagawa, Japan. 38Department of Neurosurgery, Goshik Hospital, Amagasaki, Hyogo, Japan. 39Department of Neurosurgery, Mie University Hospital, Tsu, Mie, Japan. 40Cerebrovascular Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan. 41Department of Neurological Science, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. 42Department of Neurology, Kobe Central Hospital, Kobe, Hyogo, Japan. 43Department of Neurology, Hiroshima Prefectural Hospital, Hiroshima, Japan. 44Department of Neurosurgery, Hakodate Neurosurgical Hospital, Hakodate, Hokkaido, Japan. 45Department of Neurosurgery, Hakodate Kinen Hospital, Kitakyushu, Fukuoka, Japan. 46Department of Neurosurgery, Tanushimaru Central Hospital, Kurume, Fukuoka, Japan. 47Department of Neurosurgery, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan. 48Department of Neurosurgery, Ube-Kohsan Central Hospital, Ube, Yamaguchi, Japan. 49Department of Neurosurgery, Hiroshima University Hospital, Hiroshima, Japan. 50Department of Neurosurgery, Osaka Medical College Hospital, Takatsuki, Osaka, Japan. 51Department of Neurosurgery, Hakodate Shintoshi Hospital, Hakodate, Hokkaido, Japan. 52Department of Neurosurgery, Kanazawa University, Kanazawa, Japan.